Researchers focused on data from nearly 78,000 adults with cardiometabolic disorders, sharing their findings at ACC.25 in Chicago.

Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.  

Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.

Drinking orange juice is associated with several interactions in the body that may help combat the risks of cardiac remodeling. 

Breast artery calcifications are already visible when radiologists review mammograms, but nothing typically happens with them. Researchers aimed to see if AI could help translate those findings into an easy-to-understand cardiovascular risk score.